Press Releases

D2M Biotherapeutics Announces First Patient Dosed in A Phase 1 Study Evaluating DM919, a Novel MICA/B Antibody for Treating Patients with Advanced Solid Tumors

Natick, Mass., April 19, 2024 — D2M Biotherapeutics, Inc. (D2M), a clinical stage biotech company focused on developing innovative therapies […]

Press Releases

D2M Biotherapeutics DM919 Investigational New Drug Application Approved by China’s National Medical Products Administration

Natick, Mass., April 1st, 2024 — D2M Biotherapeutics Inc (D2M), a clinical stage biotech company focused on developing innovative therapies

Press Releases

DM919 Receives FDA Clearance of IND Application to Treat Solid Tumors

D2M Biotherapeutics Announces FDA Clearance of Investigational New Drug (IND)Application for DM919, a Novel MICA/B Antibody for Treating Patients with